Hypera S.A. (OTCMKTS:HYPMY) Sees Significant Decline in Short Interest

Hypera S.A. (OTCMKTS:HYPMY) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 16,700 shares, a drop of 18.9% from the December 31st total of 20,600 shares. Based on an average daily trading volume, of 25,700 shares, the short-interest ratio is currently 0.6 days.

Hypera Price Performance

Hypera stock traded down $0.04 during midday trading on Friday, hitting $3.09. 2,285 shares of the company’s stock were exchanged, compared to its average volume of 8,693. Hypera has a 12-month low of $2.64 and a 12-month high of $7.12. The firm’s 50 day simple moving average is $3.08 and its 200 day simple moving average is $4.21. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.68.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.